Search

Objective: Ovarian cancer has highest mortality rate among gynecological cancers. In particular, in the case of peritoneal metastasis, the prognosis is poor. As a solution to this, hyperthermic intraperitoneal chemotherapy (HIPEC) has begun to be implemented. In this study, we sought to compare the results of HIPEC conducted at our hospital based on existing studies' results. Methods: We retrospectively reviewed the electronic medical record (EMR) of patients who were diagnosed with ovarian cancer and underwent HIPEC between January 2018 and December 2021. We reviewed EMR focusing on surgical outcomes and prognostic factors after HIPEC. Among these, the surgical results of patients who underwent HIPEC through primary or interval cytoreductive surgery (ICS) were compared with those who underwent HIPEC after recurrence. Results: Recurrence occurred in 76.5% of patients who underwent HIPEC and the average operation time was 501 minutes. The average of estimated blood loss was 796 mL, and postoperative side effects occurred in 8.8%. We compared the prognostic factors of patients who underwent ICS and HIPEC with those who took HIPEC after recurrence. The results were not significant, but both overall survival (OS) and progression free survival (PFS) were longer by 13 months and 9 months, respectively, in patients who underwent ICS and HIPEC (p=0.0694, p=0.1391). Conclusion: Based on existing study, the results of HIPEC at our hospital showed that the operation time and duration of hospitalization were longer. Although it was not a significant result, considering that OS and PFS results in ICS and HIPEC, it can be assumed that HIPEC after recurrence is not effective. [ABSTRACT FROM AUTHOR]